newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALGS
  • Aligos Therapeutics, Inc. granted non-qualified stock options for 81,100 shares to newly hired employees on January 29, 2026.
  • The grant was issued under the Company's 2024 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
  • The exercise price per share equals the closing price of Aligos' common stock on the grant date.
  • Shares subject to the grant vest over four years, with 25% vesting on the first anniversary 25% vesting on the first anniversary and the remainder vesting in equal monthly installments.
  • Vesting is contingent upon the employees' continued employment through the applicable vesting dates.
  • Aligos is a clinical-stage biopharmaceutical company developing therapies for liver and viral diseases, including HBV, MASH, obesity, 25% vesting on the first anniversary and the remainder vesting in equal monthly installments.
  • The company's pipeline targets high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
  • The press release includes forward-looking statements subject to risks inherent in drug development, clinical trials, 25% vesting on the first anniversary and the remainder vesting in equal monthly installments.